CHARLOTTE, NC — Bright Path Pharmaceuticals, LLC (privately held) today announced that Dr. Christopher W. McDaniel joins the company as Chief Scientific Officer and will lead BPP’s product development and regulatory teams.
Dr. McDaniel brings 25 years of experience in the pharma, OTC, and dietary supplement/nutraceutical experience. He has previously served as a Vice President and Chief Scientific Officer with Fleet Laboratories, and his experience includes working at Shire Pharmaceuticals, Southern Research Institute and Ethyl Chemical Corporation.He is a product developer with R&D experience in multiple formulation platforms and routes of administration leading to successful launches of five NDA products and more than 20 OTC, dietary supplement/nutraceutical, and personal care products.
He has proven experience in managing quality systems with successful inspections by FDA, international regulatory agencies, and client companies. He developed a risk-based rating system for internal manufacturing, raw materials, raw material suppliers, and contract manufacturers to prioritize focus in the management of over 100 suppliers and contract manufacturers.
Dr. McDaniel has expertise in regulatory compliance and product registrations internationally. He has functioned as the executive lead and team member in face to face meetings with US and foreign health authorities. He has been successful with medical affairs and clinical trials serving as a executive lead or team member in the planning and/or execution of more than 70 clinical trials Phases I – IV.
Mr. Quinones stated, “The company is pleased to have Dr. McDaniel join the BPP team and are excited about the experience and success he has had in product development.” Mr. Allen stated, “We need to de-risk the regulatory risk of the company and we are pleased to have a seasoned executive who possess a ton of success interacting with the FDA.”
About Bright Path Pharmaceuticals, LLC
Bright Path Pharmaceuticals, LLC is a developmental stage bio-pharmaceutical manufacturing company, dedicated to developing best-in-class continuous-flow manufacturing for the pharmaceutical sector. For more information, please visit www.brightpathrx.com.
To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Bright Path Pharmaceuticals’ plans, objectives, expectations and intentions with respect to cash flow requirements, future operations and products, and development activities, and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Bright Path Pharmaceuticals’ actual results to be materially different than those expressed in or implied by Bright Path Pharmaceuticals’ forward-looking statements. For Bright Path Pharmaceuticals, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the success and design of manufacturing facilities; and Bright Path Pharmaceuticals’ need for and ability to obtain additional financing. Bright Path Pharmaceuticals undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.